# Isothermal Nucleic Acid Amplification Market

> Isothermal Nucleic Acid Amplification Market Research Report: Size, Share, Trend Analysis By Product (Assays, Kits, & Reagents, and Systems), By Technology (Transcription Mediated Amplification (TMA), Loop-mediated Isothermal Amplification (LAMP), Strand Displacement Amplification (SDA), Helicase-dependent Amplification (HDA), Nucleic Acid Sequence-based Amplification (NASBA), Nicking Enzyme Amplification Reaction (NEAR), Single Primer Isothermal Amplification (SPIA), and Other Technologies), By Applications (Disease Diagnosis, Blood Screening, and Other Applications), By End-User (Hospitals, Reference Laboratories, Academic & Research Institutes, and Other End Users), And –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.5%
- **2024:** $ 6.04 Billion
- **2025:** $ 6.61 Billion
- **2035:** $ 16.39 Billion
- **Key Players:** Abbott Laboratories (US), Thermo Fisher Scientific (US), Roche Diagnostics (CH), Qiagen N.V. (NL), Hologic, Inc. (US), Luminex Corporation (US), Bio-Rad Laboratories, Inc. (US), Meridian Bioscience, Inc. (US), GenapSys, Inc. (US)

**Report ID:** MRFR/HC/20264-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/isothermal-nucleic-acid-amplification-market-21862

---

## Market Summary

## **Isothermal Nucleic Acid Amplification Market Overview**

As per MRFR analysis, the Isothermal Nucleic Acid Amplification Market Size was estimated at 6.04 (USD Billion) in 2024. The Isothermal Nucleic Acid Amplification Market Industry is expected to grow from 6.61 (USD Billion) in 2025 to 14.97 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 9.50% during the forecast period (2025 - 2034).

The increasing geriatric population globally and the rising prevalence of cancer and other chronic medical disorders, along with the escalating demand for efficient diagnosis and treatment alternatives, are expected to be significant market drivers for the Isothermal Nucleic Acid Amplification Market.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

**In November 2024,** HighQu released new isothermal nucleic acid amplification reagents such as ALLin BSt DNA Polymerase, ALLin Hot Start Bst Polymerase, ALLin HS Isothermal DNA Amplification Kit, and the ALLin HS Iso Colorimetric DNA Amplification Kit.

**In November 2024,** George Adedokun, Gurjit Sidhu, Morteza Alipanah, Gary P Wang and Z Hugh Fan presented a portable device designed for HIV detection, which features a unique means of sampling as well as real-time isothermal nucleic acid amplification.

**In March 2024,** BD, an international medically advanced technology corporation, registered the first subject for the AGILITY study, a competitive risk of bias study looking at the safety and efficacy of the BD Vascular Covered Stent in patients with peripheral artery disease (PAD).

## **Isothermal Nucleic Acid Amplification Market Trends**

Market CAGR for Isothermal Nucleic Acid Amplification is being driven by the increasing incidences of chronic diseases and an aging population, as well as a rise in demand for low-cost and effective diagnostics procedures. According to a World Health Organization report released in February 2022, cancer stands out as a major global cause of mortality. The report highlights that annually, approximately 400,000 children are diagnosed with cancer, with cervical cancer being the most prevalent in 23 countries.

A report published by the International Agency for Research on Cancer (IARC) in December 2020 underscores the global cancer burden, which has surged to 19.3 million cases. Consequently, the escalating prevalence of cancer worldwide has spurred an increased demand for effective therapeutic interventions, driving market growth.

Nucleic acid amplification technology finds diverse applications across the healthcare industry, spanning from research to clinical settings. Historically, polymerase chain reaction (PCR) has been the predominant amplification technique worldwide. PCR necessitates a thermal cycler to maintain various temperatures at distinct stages of the amplification process. Furthermore, the removal of contaminants is imperative for successful amplification via this technology. The thermal cycler itself incurs a significant cost, and the process of sample preparation to eliminate contaminants adds to the overall expense and duration of the procedure.

As a result, it is anticipated that throughout the projection period, demand for the Isothermal Nucleic Acid Amplification Market will increase due to the Increasing incidences of chronic diseases and an aging population and a rise in demand for low-cost and effective diagnostics procedures. Thus, driving the Isothermal Nucleic Acid Amplification Market revenue.

## **Isothermal Nucleic Acid Amplification Market Segment Insights**

### **Isothermal Nucleic Acid Amplification Market Product Insights**

The Isothermal Nucleic Acid Amplification Market segmentation, based on Product, includes Assays, Kits, & Reagents and Systems. The assays, kits, & reagents segment dominated the market, accounting for 58% of market revenue. The increasing need for molecular diagnostic methods stems from their precise, sensitive, and swift detection capabilities for infectious diseases, genetic disorders, and cancer biomarkers. Isothermal nucleic acid amplification techniques are preferred over conventional PCR methods due to their simplicity, rapidity, and cost-effectiveness. This surge in demand is driving the expansion of assays, kits, and reagents utilized in isothermal amplification methods.

**Figure 1: Isothermal Nucleic Acid Amplification Market, by Product, 2023 & 2032 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Isothermal Nucleic Acid Amplification Market Technology Insights**

The Isothermal Nucleic Acid Amplification Market segmentation, based on Technology includes Transcription Mediated Amplification (TMA), Loop-mediated Isothermal Amplification (LAMP), Strand Displacement Amplification (SDA), Helicase-dependent Amplification (HDA), Nucleic Acid Sequence-based Amplification (NASBA), Nicking Enzyme Amplification Reaction (NEAR), Single Primer Isothermal Amplification (SPIA), and Other Technologies. The loop-mediated isothermal amplification (LAMP) segment dominated the market, accounting for 58% of market revenue. The LAMP technique presents two key competitive advantages over PCR technology. Firstly, it exhibits tolerance towards PCR inhibitors, enabling direct sample analysis. Secondly, it operates at a fixed temperature, eliminating the need for a thermocycler.

These benefits position it favorably for point-of-care diagnostics, a segment witnessing notable growth. As per the World Ageing 2020 report, the global population aged 65 years and older is projected to reach 1.5 billion by 2050. Additionally, by 2050, one in six individuals worldwide will be over 65 years of age. These demographic trends suggest potential proportional growth in the studied LAMP market segment.

### **Isothermal Nucleic Acid Amplification Market Application Insights**

The Isothermal Nucleic Acid Amplification Market segmentation, based on Application, includes Disease Diagnosis, Blood Screening, and Other Applications. The blood screening segment dominated the market, accounting for 60% of market revenue. Due to the increasing, continuously rising demand for blood screening and analysis resulting from the rates of blood donation and transfusions globally, this segment has emerged as a crucial application area for isothermal amplification techniques in recent times.

### **Isothermal Nucleic Acid Amplification Market End-User Insights**

The Isothermal Nucleic Acid Amplification Market segmentation, based on Users, includes Hospitals, Reference Laboratories, Academic & Research Institutes, and Other End Users. The hospital segment dominated the market, accounting for 60% of market revenue. The hospital sector is poised to lead the market due to the growing utilization of INAAT kits in disease treatment. Moreover, the majority of diagnostic procedures are conducted under supervision, minimizing the likelihood of errors and ensuring accurate results, thus positively influencing revenue growth throughout the forecast period.

Additionally, the escalating demand for nucleic acid amplification technology within hospitals, compared to other end-use industries, is propelling growth in this segment.

## **Isothermal Nucleic Acid Amplification Market Regional Analysis**

By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. North America has secured the largest market share, primarily due to its well-established research infrastructure and the rising demand for nucleic acid amplification-based diagnostics aimed at preventing infectious diseases in the region. Moreover, the region's high per capita healthcare expenditure and increasing emphasis on point-of-care diagnostic techniques are projected to propel market growth. The per capita healthcare expenditure in North America is also expected to bolster market expansion.

According to data released by the United States Department of Commerce in 2021, healthcare spending in Canada is forecasted to reach USD 308 billion, accounting for approximately 12.7% of the country's GDP.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

**Figure 2: Isothermal Nucleic Acid Amplification Market Share By Region 2023 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe's Isothermal Nucleic Acid Amplification Market accounts for the second-largest market share as Europe is projected to maintain a prominent role in the worldwide isothermal nucleic acid amplification technology market, primarily due to the rising incidence of chronic diseases across the region. In 2022, chronic ischaemic heart disease was responsible for the majority of male deaths in Germany, totaling 42.9 thousand fatalities. Notably, among the top 10 causes of death, four were associated with cardiovascular complications, resulting in a cumulative total of 102.3 thousand deaths.

Further, the German Isothermal Nucleic Acid Amplification Market held the largest market share, and the UK Isothermal Nucleic Acid Amplification Market was the fastest-growing market in the European region.

The Asia-Pacific Isothermal Nucleic Acid Amplification Market is expected to grow at the fastest CAGR from 2025 to 2034, driven by factors such as the increasing prevalence of chronic diseases, heightened participation of market players in the region, and rising investments in research and development. Before the onset of the pandemic, ischaemic heart disease ranked as the primary cause of death in India, followed by chronic obstructive pulmonary disorder and stroke, as reported by the WHO. Collectively, these three non-communicable diseases (NCDs) accounted for approximately 226 deaths per 100,000 population in India in 2019.

Conversely, diarrhoeal diseases, tuberculosis, and neonatal conditions were responsible for 112 deaths per 100,000 population. Moreover, China’s Isothermal Nucleic Acid Amplification Market held the largest market share, and the Indian Isothermal Nucleic Acid Amplification Market was the fastest-growing market in the Asia-Pacific region.

## **Isothermal Nucleic Acid Amplification Market** **Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development to expand their product lines, which will help the Isothermal Nucleic Acid Amplification market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Isothermal Nucleic Acid Amplification industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Isothermal Nucleic Acid Amplification industry to benefit clients and increase the market sector. In recent years, the Isothermal Nucleic Acid Amplification industry has offered some of the most significant advantages to the entertainment and music production sectors.

Major players in the Isothermal Nucleic Acid Amplification Market, including Grifols, S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), Eiken Chemical Co., Ltd. (Japan), bioMérieux SA (France), Tecan Trading AG (Switzerland), New England Biolabs (US), QIAGEN N.V. (Germany) are attempting to increase market demand by investing in research and development operations.

Abbott Laboratories engages in the discovery, development, manufacturing, and distribution of a diverse portfolio of healthcare products, spanning branded generic pharmaceuticals, diagnostic systems, pediatric and adult nutritional products, medical devices, minerals and nutrition products, and dietary supplements. Its medical device offerings include heart failure, electrophysiology, rhythm management, vascular and structural heart devices, and neuromodulation devices. The company operates research and development facilities across the United States, Colombia, India, Singapore, Spain, and the United Kingdom, with manufacturing facilities worldwide. Abbott markets its products across North America, Latin America, the Middle East, Europe, Asia-Pacific, and Africa.

Headquartered in Abbott Park, Illinois, United States, Abbott gained approval from Health Canada for its ID NOW rapid COVID-19 testing device for Canadian use in September 2020.

Becton Dickinson and Company is a leading medical technology company specializing in the manufacture and distribution of medical devices, reagents, and instruments. Its extensive product line includes syringes, intravenous catheters, infusion pumps, automated medication dispensing systems, pre-fillable drug delivery systems, respiratory ventilation equipment, diagnostic equipment, and consumables for diagnostic specimen collection. BD also offers instruments and reagent systems for detecting various infectious diseases and cancers, as well as clinical research tools.

Serving life science researchers, healthcare institutions, clinical laboratories, the pharmaceutical industry, and the general public, BD markets its products across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. Headquartered in New Jersey, United States, BD remains a key player in the medical technology sector.

### **Key Companies in the Isothermal Nucleic Acid Amplification Market Include**

### Isothermal Nucleic Acid Amplification Market Developments

- **Q2 2024: Twist Bioscience Launches New Isothermal Amplification Assay for Infectious Disease Detection** Twist Bioscience announced the commercial launch of a new isothermal nucleic acid amplification assay designed for rapid detection of infectious diseases, expanding its molecular diagnostics portfolio.
- **Q2 2024: Abbott Receives CE Mark for ID NOW 2, Next-Generation Isothermal Molecular Platform** Abbott announced it has received CE Mark for its ID NOW 2 platform, an upgraded isothermal nucleic acid amplification device for point-of-care molecular testing, enabling faster and more accurate diagnostics in Europe.
- **Q2 2024: Molbio Diagnostics Announces Strategic Partnership with Roche for Isothermal NAAT Distribution in Asia** Molbio Diagnostics entered a strategic partnership with Roche to distribute its isothermal nucleic acid amplification technology-based diagnostic kits across select Asian markets, aiming to expand access to rapid molecular testing.
- **Q3 2024: QuantuMDx Raises $30 Million in Series C Funding to Advance Isothermal NAAT Platform** QuantuMDx secured $30 million in Series C funding to accelerate development and commercialization of its proprietary isothermal nucleic acid amplification technology for decentralized molecular diagnostics.
- **Q3 2024: BioFire Diagnostics Opens New Manufacturing Facility for Isothermal NAAT Reagents in Utah** BioFire Diagnostics, a subsidiary of bioMérieux, inaugurated a new manufacturing facility in Utah dedicated to producing reagents for its isothermal nucleic acid amplification tests, aiming to meet growing global demand.
- **Q3 2024: Lucira Health Appoints New CEO to Drive Expansion of Isothermal Molecular Testing Portfolio** Lucira Health announced the appointment of a new Chief Executive Officer, focusing on scaling up its isothermal nucleic acid amplification-based molecular testing solutions for infectious diseases.
- **Q4 2024: Atila BioSystems Receives FDA Emergency Use Authorization for Isothermal COVID-19 Test** Atila BioSystems received FDA Emergency Use Authorization for its isothermal nucleic acid amplification-based COVID-19 test, enabling broader deployment in clinical and point-of-care settings in the United States.
- **Q4 2024: Eiken Chemical and Thermo Fisher Scientific Announce Co-Development Agreement for LAMP-based Diagnostics** Eiken Chemical and Thermo Fisher Scientific entered a co-development agreement to create new loop-mediated isothermal amplification (LAMP) diagnostic assays for infectious disease detection.
- **Q1 2025: Genomtec Secures $15 Million in Series B Funding to Scale Isothermal NAAT Platform** Genomtec raised $15 million in Series B funding to expand manufacturing and commercialization of its portable isothermal nucleic acid amplification technology for rapid diagnostics.
- **Q1 2025: Meridian Bioscience Launches New Isothermal Amplification Test for Food Safety Applications** Meridian Bioscience launched a new isothermal nucleic acid amplification test targeting foodborne pathogens, expanding its product offerings in the food safety diagnostics market.
- **Q2 2025: HiberGene Diagnostics Announces Partnership with Siemens Healthineers for Global Distribution** HiberGene Diagnostics partnered with Siemens Healthineers to distribute its isothermal nucleic acid amplification-based diagnostic products globally, aiming to increase market penetration.
- **Q2 2025: Cue Health Receives Health Canada Approval for Isothermal Molecular COVID-19 Test** Cue Health received regulatory approval from Health Canada for its isothermal nucleic acid amplification-based COVID-19 test, allowing commercial sales in the Canadian market.

## **Isothermal Nucleic Acid Amplification** **Market Segmentation**

### **Isothermal Nucleic Acid Amplification Market Product Outlook**

### **Isothermal Nucleic Acid Amplification Market Technology Outlook**

### **Isothermal Nucleic Acid Amplification Market Application Outlook**

### **Isothermal Nucleic Acid Amplification Market End-User Outlook**

### **Isothermal Nucleic Acid Amplification Market** **Regional Outlook**

## Market Drivers

### Focus on Point-of-Care Testing

The Isothermal Nucleic Acid Amplification Market is aligning with the growing emphasis on point-of-care (POC) testing. This shift is largely influenced by the need for accessible and efficient diagnostic solutions in remote and underserved areas. Isothermal amplification technologies are particularly suited for POC applications due to their simplicity and rapid results. The market for POC testing is expected to reach USD 5 billion by 2025, with isothermal methods playing a pivotal role in this growth. The convenience of conducting tests outside traditional laboratory settings is likely to enhance patient outcomes and streamline healthcare processes, thereby reinforcing the market's trajectory.

### Rising Prevalence of Infectious Diseases

The Isothermal Nucleic Acid Amplification Market is significantly impacted by the rising prevalence of infectious diseases worldwide. The increasing incidence of diseases such as tuberculosis, HIV, and various viral infections necessitates the development of efficient diagnostic tools. Isothermal amplification methods provide a rapid and reliable means of detecting these pathogens, which is crucial for timely treatment and containment. The World Health Organization has reported a steady increase in the number of reported cases, further emphasizing the need for advanced diagnostic solutions. This trend is expected to drive market growth, with projections indicating a potential market expansion of over 15% in the coming years.

### Increased Demand for Rapid Testing Solutions

The Isothermal Nucleic Acid Amplification Market is witnessing heightened demand for rapid testing solutions, particularly in the fields of infectious disease diagnostics and food safety. The ability to deliver results within a short timeframe is becoming increasingly critical for healthcare providers and regulatory agencies. This demand is reflected in the market's expansion, with estimates suggesting a market size of over USD 1 billion by 2026. The urgency for timely diagnosis, especially in emergency situations, is propelling the adoption of isothermal amplification techniques, which offer quick turnaround times compared to traditional methods. Consequently, this trend is likely to drive further investments in research and development within the industry.

### Growing Investment in Research and Development

The Isothermal Nucleic Acid Amplification Market is benefiting from growing investments in research and development (R&D) initiatives. As stakeholders recognize the potential of isothermal amplification technologies, funding for innovative projects is increasing. This investment is aimed at enhancing the sensitivity and specificity of diagnostic tests, as well as expanding their applications across various fields, including veterinary diagnostics and food safety. The market is projected to see a substantial increase in R&D spending, with estimates suggesting a growth rate of around 12% annually. This focus on innovation is likely to yield new products and solutions, further propelling the market forward.

### Technological Advancements in Isothermal Nucleic Acid Amplification

The Isothermal Nucleic Acid Amplification Market is experiencing a surge in technological advancements that enhance the efficiency and accuracy of nucleic acid testing. Innovations such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA) are gaining traction. These technologies allow for rapid amplification of nucleic acids at a constant temperature, eliminating the need for complex thermal cycling equipment. As a result, the market is projected to grow at a compound annual growth rate (CAGR) of approximately 10% over the next five years. This growth is driven by the increasing adoption of these technologies in various applications, including clinical diagnostics and environmental monitoring, thereby expanding the market's reach.

## Future Outlook

The Isothermal Nucleic Acid Amplification Market is projected to grow at a 9.5% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for rapid diagnostics.

**New opportunities:**

- Development of portable diagnostic devices for remote testing
- Integration of AI for enhanced data analysis in diagnostics
- Expansion into emerging markets with tailored solutions

By 2035, the market is expected to achieve substantial growth, solidifying its role in global diagnostics.

## Segment Insights

### By Product: Assays, Kits, & Reagents (Largest) vs. Systems (Fastest-Growing)

In the Isothermal Nucleic Acid Amplification Market, the 'Assays, Kits, & Reagents' segment holds the largest share due to its widespread adoption in laboratory settings and research institutions. This segment has become the backbone of nucleic acid testing, providing reliable and efficient solutions for various applications, including disease diagnostics and genetic research. Conversely, the 'Systems' segment, while smaller, is emerging as a key player, driven by technological advancements that enhance user-friendliness and diagnostic capabilities.

Assays, Kits, & Reagents (Dominant) vs. Systems (Emerging)

The 'Assays, Kits, & Reagents' segment is characterized by a diverse array of products designed to facilitate nucleic acid amplification processes. This segment dominates the market due to its established presence and consistent demand in clinical and research laboratories. Meanwhile, the 'Systems' segment represents an emerging trend with innovative platforms that streamline the amplification process, increasing efficiency and accuracy. Coupled with their growing adoption in point-of-care settings, these systems are gaining traction, driven by the need for rapid diagnostics and enhanced automation in laboratory workflows.

### By Technology: Loop-mediated Isothermal Amplification (LAMP) (Largest) vs. Transcription Mediated Amplification (TMA) (Fastest-Growing)

In the Isothermal Nucleic Acid Amplification Market, the technology segment is diversely distributed among various methods. Loop-mediated Isothermal Amplification (LAMP) currently holds the largest share, largely due to its efficiency, simplicity, and ability to provide rapid results, making it a preferred choice in diagnostics. Other methods, including Transcription Mediated Amplification (TMA) and Strand Displacement Amplification (SDA), also contribute to the market, with each technique having its unique advantages in specific applications. The growth trends in this segment are heavily influenced by advances in molecular diagnostics and the increasing demand for point-of-care testing. TMA is identified as the fastest-growing technique, driven by the need for rapid and sensitive detection of pathogens in clinical settings. The rise in infectious diseases and genetic disorders drives innovation and adoption of these technologies, highlighting a trend towards more accessible and efficient diagnostic methods.

Technology: LAMP (Dominant) vs. TMA (Emerging)

Loop-mediated Isothermal Amplification (LAMP) is a dominant technology in the Isothermal Nucleic Acid Amplification Market, offering high sensitivity and specificity. Its operational simplicity allows for broad applications, particularly in resource-limited settings. LAMP's ability to amplify nucleic acids with minimal equipment has made it popular in diagnostic laboratories and field settings. In contrast, Transcription Mediated Amplification (TMA) is emerging rapidly, propelled by its accuracy in detecting RNA targets. TMA is particularly valuable in testing respiratory viruses and sexually transmitted infections. Its scalability and efficiency position it well for future growth, aligning with the overall trend of increasing demand for rapid and point-of-care diagnostics.

### By Application: Disease Diagnosis (Largest) vs. Blood Screening (Fastest-Growing)

Within the Isothermal Nucleic Acid Amplification Market, the application segments are primarily categorized into Disease Diagnosis, Blood Screening, and Other Applications. Disease Diagnosis holds the largest market share, driven by the increasing prevalence of infectious diseases and genetic disorders that necessitate rapid diagnostic solutions. Blood Screening, while currently smaller, is emerging as a significant segment due to rising awareness of blood-borne illnesses and the demand for safety in transfusions.

Application: Disease Diagnosis (Dominant) vs. Blood Screening (Emerging)

Disease Diagnosis is the dominant application area, characterized by its essential role in the early detection and management of various medical conditions. Its supremacy is fueled by advancements in diagnostic technologies and a pressing need for rapid, reliable results. Conversely, Blood Screening is an emerging field that is gaining traction thanks to heightened awareness around transfusion safety and blood-borne infections. The segment is experiencing rapid technological innovation, with isothermal nucleic acid amplification providing effective and quick detection methods, making it a pivotal area for growth in the coming years.

### By End User: Hospitals (Largest) vs. Reference Laboratories (Fastest-Growing)

In the Isothermal Nucleic Acid Amplification Market, the end user segment showcases a diverse landscape with hospitals taking the lead as the largest contributing sector. Hospitals utilize isothermal amplification technologies for rapid and accurate diagnostic testing, significantly impacting patient care and clinical outcomes. In parallel, reference laboratories are rapidly emerging, driven by their expertise in complex testing and a growing demand for high-throughput capabilities. Together, these two sectors characterize the dynamic nature of this market, where hospitals hold a substantial market share while reference laboratories drive innovation and efficiency. The growth trends in this segment are reflective of increasing healthcare demands and technological advancements. Hospitals are continually integrating innovative nucleic acid testing into routine diagnostics, thereby enhancing patient management strategies. Simultaneously, reference laboratories are leveraging isothermal nucleic acid amplification techniques to boost their testing throughput, catering to the growing market need for faster and more accurate results. This bifocal growth trajectory underscores the critical role both hospitals and reference laboratories play in shaping the future of nucleic acid amplification approaches.

Hospitals (Dominant) vs. Academic & Research Institutes (Emerging)

Hospitals serve as the dominant end user of isothermal nucleic acid amplification technologies, utilizing these tools to enhance diagnostic accuracy and reduce turnaround times for critical test results. The integration of these technologies into clinical workflows has become a strategic priority, resulting in improved patient care and operational efficiency. On the other hand, academic and research institutes represent an emerging segment in this market. These institutions are increasingly adopting isothermal amplification methods for their research applications, including infectious disease studies and genetic research. Their focus on innovation and academic inquiry is driving demand for new methodologies and contributing to the overall growth of the market, as they explore novel applications of nucleic acid amplification within various research fields.

## Regional Market Share Analysis

### North America : Innovation and Market Leadership

North America is the largest market for isothermal nucleic acid amplification, holding approximately 45% of the global share. The region's growth is driven by increasing demand for rapid diagnostic tests, particularly in the wake of the COVID-19 pandemic. Regulatory support from agencies like the FDA has accelerated the approval of innovative diagnostic solutions, fostering a competitive environment. The United States leads the market, with significant contributions from Canada. Key players such as Abbott Laboratories and Thermo Fisher Scientific are at the forefront, leveraging advanced technologies to enhance product offerings. The competitive landscape is characterized by continuous innovation and strategic partnerships, ensuring a robust supply chain and market presence.

### Europe : Regulatory Support and Growth

Europe is the second-largest market for isothermal nucleic acid amplification, accounting for about 30% of the global market share. The region benefits from strong regulatory frameworks that promote innovation in diagnostics. The European Medicines Agency (EMA) has been instrumental in streamlining the approval process for new technologies, which has spurred market growth and adoption of isothermal amplification methods. Leading countries include Germany, France, and the UK, where significant investments in healthcare infrastructure and research are evident. Major players like Roche Diagnostics and Qiagen N.V. are expanding their portfolios to include isothermal amplification products. The competitive landscape is marked by collaborations between public and private sectors, enhancing research and development capabilities.

### Asia-Pacific : Rapid Growth and Adoption

Asia-Pacific is witnessing rapid growth in the isothermal nucleic acid amplification market, holding approximately 20% of the global share. The region's expansion is driven by increasing healthcare investments, rising prevalence of infectious diseases, and a growing focus on personalized medicine. Countries like China and India are leading this growth, supported by favorable government initiatives and funding for healthcare advancements. China is the largest market in the region, followed by India and Japan. The competitive landscape features both established players and emerging startups, with companies like Hologic, Inc. and Luminex Corporation making significant inroads. The region's market is characterized by a strong emphasis on research and development, fostering innovation in diagnostic technologies.

### Middle East and Africa : Untapped Potential and Growth

The Middle East and Africa region is gradually emerging in the isothermal nucleic acid amplification market, currently holding about 5% of the global share. The growth is primarily driven by increasing healthcare expenditure, rising awareness of infectious diseases, and the need for rapid diagnostic solutions. Countries like South Africa and the UAE are leading the way, with government initiatives aimed at improving healthcare infrastructure. The competitive landscape is still developing, with a mix of local and international players. Companies are focusing on establishing partnerships to enhance their market presence. The region presents significant opportunities for growth, particularly in expanding access to advanced diagnostic technologies and improving healthcare outcomes.

## Competitive Benchmarking

The Isothermal Nucleic Acid Amplification Market is currently characterized by a dynamic competitive landscape, driven by advancements in molecular diagnostics and the increasing demand for rapid testing solutions. Key players such as Abbott Laboratories (US), Thermo Fisher Scientific (US), and Roche Diagnostics (CH) are strategically positioned to leverage their extensive research capabilities and established market presence. Abbott Laboratories (US) focuses on innovation in point-of-care testing, while Thermo Fisher Scientific (US) emphasizes its broad portfolio of molecular diagnostic tools. Roche Diagnostics (CH) is known for its commitment to integrating cutting-edge technology into its diagnostic solutions. Collectively, these strategies foster a competitive environment that prioritizes rapid innovation and responsiveness to market needs.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive technological advancements. This competitive structure encourages smaller firms to innovate and differentiate their offerings, thereby contributing to a vibrant market ecosystem.
In August 2025, Abbott Laboratories (US) announced the launch of a new isothermal amplification platform designed for rapid detection of infectious diseases. This strategic move is significant as it aligns with the growing demand for quick and accurate diagnostic solutions, particularly in decentralized settings. By enhancing its product offerings, Abbott aims to solidify its market leadership and respond effectively to evolving healthcare needs.
In September 2025, Thermo Fisher Scientific (US) expanded its collaboration with various research institutions to develop next-generation isothermal amplification technologies. This partnership is crucial as it not only accelerates innovation but also positions Thermo Fisher at the forefront of emerging diagnostic trends. The collaboration underscores the importance of strategic alliances in fostering technological advancements and enhancing product capabilities.
In July 2025, Roche Diagnostics (CH) unveiled a new line of isothermal amplification assays that integrate artificial intelligence for improved accuracy and efficiency. This development is indicative of the growing trend towards AI integration in diagnostics, which could potentially revolutionize the way tests are conducted and interpreted. Roche's focus on AI reflects a broader industry shift towards leveraging technology to enhance diagnostic precision and operational efficiency.
As of October 2025, current competitive trends in the Isothermal Nucleic Acid Amplification Market include a pronounced emphasis on digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver rapid, accurate diagnostic solutions.

## Recent News & Developments

- **Q2 2024: Twist Bioscience Launches New Isothermal Amplification Assay for Infectious Disease Detection** Twist Bioscience announced the commercial launch of a new isothermal nucleic acid amplification assay designed for rapid detection of infectious diseases, expanding its molecular diagnostics portfolio.
- **Q2 2024: Abbott Receives CE Mark for ID NOW 2, Next-Generation Isothermal Molecular Platform** Abbott announced it has received CE Mark for its ID NOW 2 platform, an upgraded isothermal nucleic acid amplification device for point-of-care molecular testing, enabling faster and more accurate diagnostics in Europe.
- **Q2 2024: Molbio Diagnostics Announces Strategic Partnership with Roche for Isothermal NAAT Distribution in Asia** Molbio Diagnostics entered a strategic partnership with Roche to distribute its isothermal nucleic acid amplification technology-based diagnostic kits across select Asian markets, aiming to expand access to rapid molecular testing.
- **Q3 2024: QuantuMDx Raises $30 Million in Series C Funding to Advance Isothermal NAAT Platform** QuantuMDx secured $30 million in Series C funding to accelerate development and commercialization of its proprietary isothermal nucleic acid amplification technology for decentralized molecular diagnostics.
- **Q3 2024: BioFire Diagnostics Opens New Manufacturing Facility for Isothermal NAAT Reagents in Utah** BioFire Diagnostics, a subsidiary of bioMérieux, inaugurated a new manufacturing facility in Utah dedicated to producing reagents for its isothermal nucleic acid amplification tests, aiming to meet growing global demand.
- **Q3 2024: Lucira Health Appoints New CEO to Drive Expansion of Isothermal Molecular Testing Portfolio** Lucira Health announced the appointment of a new Chief Executive Officer, focusing on scaling up its isothermal nucleic acid amplification-based molecular testing solutions for infectious diseases.
- **Q4 2024: Atila BioSystems Receives FDA Emergency Use Authorization for Isothermal COVID-19 Test** Atila BioSystems received FDA Emergency Use Authorization for its isothermal nucleic acid amplification-based COVID-19 test, enabling broader deployment in clinical and point-of-care settings in the United States.
- **Q4 2024: Eiken Chemical and Thermo Fisher Scientific Announce Co-Development Agreement for LAMP-based Diagnostics** Eiken Chemical and Thermo Fisher Scientific entered a co-development agreement to create new loop-mediated isothermal amplification (LAMP) diagnostic assays for infectious disease detection.
- **Q1 2025: Genomtec Secures $15 Million in Series B Funding to Scale Isothermal NAAT Platform** Genomtec raised $15 million in Series B funding to expand manufacturing and commercialization of its portable isothermal nucleic acid amplification technology for rapid diagnostics.
- **Q1 2025: Meridian Bioscience Launches New Isothermal Amplification Test for Food Safety Applications** Meridian Bioscience launched a new isothermal nucleic acid amplification test targeting foodborne pathogens, expanding its product offerings in the food safety diagnostics market.
- **Q2 2025: HiberGene Diagnostics Announces Partnership with Siemens Healthineers for Global Distribution** HiberGene Diagnostics partnered with Siemens Healthineers to distribute its isothermal nucleic acid amplification-based diagnostic products globally, aiming to increase market penetration.
- **Q2 2025: Cue Health Receives Health Canada Approval for Isothermal Molecular COVID-19 Test** Cue Health received regulatory approval from Health Canada for its isothermal nucleic acid amplification-based COVID-19 test, allowing commercial sales in the Canadian market.

## **Isothermal Nucleic Acid Amplification Market** 

## Report Scope

| MARKET SIZE 2024 | 6.04(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.614(USD Billion) |
| MARKET SIZE 2035 | 16.39(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Thermo Fisher Scientific (US), Roche Diagnostics (CH), Qiagen N.V. (NL), Hologic, Inc. (US), Luminex Corporation (US), Bio-Rad Laboratories, Inc. (US), Meridian Bioscience, Inc. (US), GenapSys, Inc. (US) |
| Segments Covered | Product, Technology, Applications, End-User |
| Key Market Opportunities | Advancements in rapid diagnostics and point-of-care testing drive growth in the Isothermal Nucleic Acid Amplification Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the Isothermal Nucleic Acid Amplification Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Isothermal Nucleic Acid Amplification Market by 2035?**
A: The projected market valuation for the Isothermal Nucleic Acid Amplification Market is expected to reach 16.39 USD Billion by 2035.

**Q: What was the market valuation of the Isothermal Nucleic Acid Amplification Market in 2024?**
A: The overall market valuation was 6.04 USD Billion in 2024.

**Q: What is the expected CAGR for the Isothermal Nucleic Acid Amplification Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Isothermal Nucleic Acid Amplification Market during the forecast period 2025 - 2035 is 9.5%.

**Q: Which companies are considered key players in the Isothermal Nucleic Acid Amplification Market?**
A: Key players in the market include Abbott Laboratories, Thermo Fisher Scientific, Roche Diagnostics, Qiagen N.V., Hologic, Inc., Luminex Corporation, Bio-Rad Laboratories, Meridian Bioscience, and GenapSys.

**Q: What are the projected revenues for Assays, Kits, & Reagents by 2035?**
A: The projected revenue for Assays, Kits, & Reagents is expected to reach 9.66 USD Billion by 2035.

**Q: How much is the market for Loop-mediated Isothermal Amplification (LAMP) expected to grow by 2035?**
A: The market for Loop-mediated Isothermal Amplification (LAMP) is projected to grow to 4.0 USD Billion by 2035.

**Q: What is the anticipated revenue for Disease Diagnosis applications in 2035?**
A: The anticipated revenue for Disease Diagnosis applications is expected to reach 6.5 USD Billion by 2035.

**Q: What segment is expected to generate the highest revenue among end users by 2035?**
A: Hospitals are expected to generate the highest revenue among end users, projected to reach 6.39 USD Billion by 2035.

**Q: What is the projected revenue for Blood Screening applications by 2035?**
A: The projected revenue for Blood Screening applications is expected to reach 4.0 USD Billion by 2035.

**Q: Which technology segment is expected to see the most growth by 2035?**
A: The 'Other Technologies' segment is expected to see substantial growth, projected to reach 5.89 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/isothermal-nucleic-acid-amplification-market-21862*